Answers are grounded in this paper and cite their sources.
Amivantamab is a bispecific anti-EGFR and anti-MET monoclonal antibody approved for advanced non-small cell lung cancer. While dermatologic toxicities such as rash and scalp dermatitis are common, erosive pustular dermatosis of the scalp remains exceedingly rare. We describe a woman in her 70s with stage IV NSCLC who developed EPDS initially and subsequently was complicated by cellulitis. Conventional therapies yielded minimal benefits. A combined approach involving ultrasound-assisted debridement, amniotic allograft placement, and topical propranolol resulted in substantial wound healing and re-epithelialization. This case demonstrates a severe adverse effect of Amivantamab and an innovative management strategy for complex dermatologic complications in oncology patients.
No takes yet. Share an insight, caveat, or question.
Morakbian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: